Anti-EGFR-IL-dox (Swiss Group for Clinical Cancer Research)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-EGFR-IL-dox (Swiss Group for Clinical Cancer Research)
Drug Alias Nameanti-EGFR-immunoliposomes loaded with doxorubicin
ClassificationBiologics
Mechanisms of ActionEpidermal growth factor receptor erbB1 modulators
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSchweizerische Arbeitsgemeinschaft Für Klinische Krebsforschung
China Registration ClassN/A

Develop Information

Active CompaniesSchweizerische Arbeitsgemeinschaft Für Klinische Krebsforschung
Inactive CompaniesSwiss Group for Clinical Cancer Research (SAKK)
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A